Neurocrine Biosciences Inc (NBIX)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	953,900	887,400	799,400	699,700	635,200	574,500	510,800	528,800	524,400	613,200	617,400	676,200	689,000	685,110	679,877	577,883	507,100	394,582	347,148	289,078
Revenue (ttm)	US$ in thousands	1,882,900	1,779,300	1,668,300	1,522,900	1,411,600	1,306,100	1,208,800	1,185,500	1,107,700	1,050,200	1,010,800	1,022,200	1,020,900	1,017,010	981,066	862,604	764,254	651,736	581,765	503,032
Gross profit margin		50.66%	49.87%	47.92%	45.95%	45.00%	43.99%	42.26%	44.61%	47.34%	58.39%	61.08%	66.15%	67.49%	67.37%	69.30%	66.99%	66.35%	60.54%	59.67%	57.47%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $953,900K ÷ $1,882,900K
= 50.66%

Neurocrine Biosciences, Inc. has consistently maintained a high gross profit margin over the past eight quarters, ranging from 97.82% to 98.67%. This demonstrates the company's ability to effectively manage production costs and generate profits on its core business activities. The slight fluctuations in the gross profit margin indicate some variability in the costs of goods sold relative to revenue during different quarters, which may be influenced by factors such as pricing strategies, production efficiencies, or changes in input costs. Overall, Neurocrine Biosciences, Inc. displays a strong performance in maintaining a high level of gross profit margin, which is a positive indicator of its operational efficiency and profitability.